Tharimmune, Inc. — Remuneration Information 2022

Jun 23, 2022

DEFA14A 1 formdefa14a.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary
Proxy Statement |
| --- | --- |
| ☐ | Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive
Proxy Statement |
| ☒ | Definitive
Additional Materials |
| ☐ | Soliciting
Material under § 240.14a-12 |

HILLSTREAM BIOPHARMA, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

| ☒ | No
fee required |
| --- | --- |
| ☐ | Fee
paid previously with preliminary materials. |
| ☐ | Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11 |

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

HILLSTREAM BIOPHARMA, INC.

1200 Route 22 East, Suite 2000

Bridgewater, NJ 08807

Explanatory Note

On June 17, 2022, Hillstream BioPharma, Inc. (the “Company”) filed its Definitive Proxy Statement on Schedule 14A (the “Original Proxy Statement”) and the related proxy card (the “Original Proxy Card”) with the Securities and Exchange Commission. The Original Proxy Card inadvertently included a column for stockholders to abstain from voting with respect to the director nominees named in the Original Proxy Statement. The purpose of filing this supplement is to include a revised proxy card to correct such error. No other changes have been made to the Original Proxy Statement.

Field: Page; Sequence: 2

Field: /Page

Field: Page; Sequence: 3

Field: /Page

Field: Page; Sequence: 4; Options: Last

Field: /Page